PARIS, March 22, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS) , a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced it will present the full results of the safety, pharmacokinetics and pharmacodynamics of Sarconeos (BIO101), the Company’s lead drug candidate for the treatment of sarcopenia, in healthy elderly volunteers in the SARA-PK clinical study, as well as three other scientific studies, at the 7 th International Conference on Frailty & Sarcopenia Research, held April 27-29 th 2017 in Barcelona, Spain.
Stanislas Veillet CEO BIOPHYTIS , said: “ We are proud to present the full results of the SARA-PK clinical study at the leading international conference, confirming the potential of Sarconeos in the treatment of sarcopenia. Several other studies have been selected, demonstrating the energy and originality of our scientific and medical teams, among the most active in the industry, which today are focused on the launch of the SARA-OBS/INT international clinical study.”
Oral presentation - April 28 th :
SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of BIO101 in healthy young and older volunteers. Wally Dioh 1 , Susanna Del Signore 1 , Philippe Dupont 1 , Pierre Dilda 1 , René Lafont 1,2 , Stanislas Veillet 1 (2017). 1 BIOPHYTIS, Paris, France , 2 Sorbonne Universités, UPMC Univ Paris 6, CNRS - Laboratoire BIOSIPE, Paris France The complete results of the SARA-PK clinical study will be presented, confirming the good safety and pharmacokinetics profile of Sarconeos (BIO101) in healthy elderly volunteers.
| Posters: | |
| Title: | BIO103, a second-generation compound for the treatment of sarcopenia. From anabolic properties to the reversion of aging-related functional loss. |
| Authors: | Pierre Dilda 1 , Anne-Sophie Foucault 1 , Sophie Raynal 1 , Christel Carbonne 2 , Jean-Denis Durand 2 , Stanislas Veillet 1 , Waly Dioh 1 , René Lafont 3 (2017). |
| 1 BIOPHYTIS, Paris, France, 2 Metabrain Research, Chilly-Mazarin, France, 3 Sorbonne Universités, Laboratoire BIOSIPE, Paris, France | |
| The effects of BIO103, the second-generation drug candidate in pre-clinical development in sarcopenic mice are presented. BIO103 efficiently compensates the effect of aging on mobility, confirming its potential in the treatment of Sarcopenia and other muscular dystrophies. | |
| Title: | Loss of muscular function as a result of aging, obesity and immobilization: a mouse model for pharmacological intervention. |
| Authors: | Anne-Sophie Foucault 1 , Pierre Dilda 1 , Stanislas Veillet 1 , Waly Dioh 1 , Arnaud Ferry 2 , René Lafont. (2017). |
| 1 BIOPHYTIS, Paris, France, 2 Sorbonne Universités, UPMC, Inserm, CNRS – Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France | |
| A new sarcopenic animal model is being presented, allowing the evaluation of the effect of drugs such as Sarconeos (BIO101) and BIO103 on muscle quality and mobility over the course of aging. | |
| Title: | Patient Reported Outcomes (ePROs) – SarQoL, SF-36 and TSD-OC - in ageing related Sarcopenia. SARA-OBS, a six-month observational clinical trial. |
| Authors: | Susanna Del Signore 1 , Waly Dioh 1 , Gianluca Zia 2 , Stefania Del Signore 2 , Stanislas Veillet 1 . (2017). |
| 1 BIOPHYTIS, Paris, France, 2 Bluecompanion ltd, London, United Kingdom. | |
| A model of an electronic observation notebook (or Electronic Patient Reported Outcomes i.e. ePROs) developed for SARA clinical studies is being presented. The data gathered is automatically stored in SARA-DATA, the database built for automatically storing and following in real-time SARA clinical data. | |
For more information on the ICFSR program please see: http://www.frailty-sarcopenia.com/programme.pdf
About SARCONEOS (BIO101) Sarconeos is a first in class drug candidate based on the activation of the MAS receptor (major player of the renin-angiotensin system) restoring muscular anabolism, inhibiting myostatin, and that has demonstrated meaningful activity in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle, leading to loss of mobility in elderly people. This condition, for which no medical treatment currently exists, was first described in 1993 and has entered the International Classification of Diseases (M62.84) in 2016. It affects more than 50 million people worldwide.
About BIOPHYTIS: BIOPHYTIS SA ( www.biophytis.com ), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute
BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825).
For more information: http://www.biophytis.com
Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website ( www.amf-france.org ) or on BIOPHYTIS’ website ( www.biophytis.com ).
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.
| BIOPHYTIS Stanislas VEILLET CEO contact@biophytis.com Tel : +33 (0) 1 41 83 66 00 | Citigate Dewe Rogerson International press Laurence BAULT/Antoine DENRY Laurence.bault@citigate.fr/antoine.denry@citigate.fr Tel : +33 (0)1 53 32 84 78 Mob : +33(0)6 64 12 53 61 Milestones Press and investor relations Bruno ARABIAN barabian@milestones.fr Tel : +33 (0) 1 83 62 34 84 Mob : +33 (0) 6 87 88 47 26 | LifeSci Advisors Chris MAGGOS Managing Director, Europe chris@lifesciadvisors.com Tel : +41 79 367 6254 |
